A Single-center, Randomized, Double-blind, Placebo-controlled, 6 Month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Trial Profile

A Single-center, Randomized, Double-blind, Placebo-controlled, 6 Month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Ibudilast (Primary) ; Riluzole
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Sponsors MediciNova
  • Most Recent Events

    • 07 Dec 2017 Top-line results presented in a MediciNova media release.
    • 01 Nov 2017 According to a MediciNova media release, data will be presented as oral presentation at the 28th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease)
    • 18 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top